Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma

8 december 2020 uppdaterad av: University of Washington

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy

This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in patients with prostate adenocarcinoma. Studying the biomarkers in the laboratory may help doctors know the impact of androgen deprivation on metabolic, brain and cardiovascular endpoints.

Studieöversikt

Status

Avslutad

Detaljerad beskrivning

OUTLINE:

Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.

Studietyp

Observationell

Inskrivning (Faktisk)

2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Washington
      • Seattle, Washington, Förenta staterna, 98109
        • Fred Hutch/University of Washington

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Participants with prostate adenocarcinoma

Beskrivning

Inclusion Criteria:

  • Signed informed consent
  • Histologically confirmed adenocarcinoma of the prostate
  • Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
  • No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
  • Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:

    • Prior myocardial infarction >= 30 days before enrollment
    • Prior revascularization procedure >= 30 days before consent, including:

      • Coronary artery stent placement or balloon angioplasty
      • Coronary artery bypass graft surgery
      • Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
      • Carotid endarterectomy surgery
      • Vascular bypass surgery of the iliac, femoral, or popliteal artery
    • Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
    • Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
    • Ankle-brachial pressure index < 0.9 at any time point before enrollment
  • Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months

Exclusion Criteria:

  • No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
  • Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
  • Plans to start or continue treatment with an investigational product after enrollment
  • Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
  • Prior or planned surgical castration
  • Poorly controlled hypertension at time of study entry, as judged by the investigator
  • Myocardial infarction or stroke < 30 days prior to enrollment
  • Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
  • Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
  • Mental incapacity or language barrier precluding adequate understanding or cooperation
  • Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
  • Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
  • Estimated glomerular filtration rate (eGFR) < 45
  • History of allergy to gadolinium contrast agent

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
Sidostudier
Undergo clinical evaluations

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
Tidsram: 12 Months
Change From Baseline visual characterization scan results at 12 months
12 Months
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
Tidsram: 12 Months
Change from baseline standardized uptake values in select regions of interest at 12 months
12 Months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Cognitive test results: Story recall
Tidsram: 12 months
Change in baseline Story Recall results at 12 months
12 months
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
Tidsram: 12 Months
Change in baseline MOCA score results at 12 months
12 Months
Cognitive Test Results: Change in Clinical Dementia Rating Scale
Tidsram: 12 Months
Change in baseline Clinical Dementia Rating Scale score at 12 months
12 Months
Cognitive Test Results: Digit span
Tidsram: 12 Months
Change in baseline Digit span results at 12 months
12 Months
Cognitive Test Results: Letter number sequencing
Tidsram: 12 Months
Change in baseline Letter number sequencing results at 12 months
12 Months
Cognitive Test Results: Stroop Test Results
Tidsram: 12 Months
Change in baseline Stroop Test Results at 12 months
12 Months
Cognitive Test Results: Symbol Digit Modalities Test
Tidsram: 12 Months
Change in baseline Symbol Digit Modalities Test score at 12 months
12 Months
Cognitive Test Results: Visuo-Spatial Learning Test
Tidsram: 12 Months
Change in baseline Visuo-Spatial Learning Test results at 12 months
12 Months
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
Tidsram: 12 Months
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
12 Months
Inflammatory and immune markers: Change in CRP
Tidsram: 12 Months
Change in baseline CRP values at 12 months
12 Months
Inflammatory and immune markers: Change in IGFBP3
Tidsram: 12 Months
Change in baseline IGFBP3 at 12 months
12 Months
Inflammatory and immune markers: Change in IGFBP1
Tidsram: 12 Months
Change in baseline IGFBP1 at 12 months
12 Months
Inflammatory and immune markers: Change in IGF-1
Tidsram: 12 Months
Change in baseline IGF-1 at 12 months
12 Months
Inflammatory and immune markers: Change in IL-6
Tidsram: 12 Months
Change in baseline IL-6 at 12 months
12 Months
Metabolic Markers: Change in HgbA1C
Tidsram: 12 Months
Change in baseline HgbA1C at 12 months
12 Months
Metabolic Markers: Change in Estradiol
Tidsram: 12 Months
Change in baseline Estradiol at 12 months
12 Months
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
Tidsram: 12 Months
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
12 Months
Metabolic Markers: Change in Leptin
Tidsram: 12 Months
Change in baseline Leptin at 12 months
12 Months
Metabolic Markers: Change in Adiponectin
Tidsram: 12 Months
Change in baseline Adiponectin at 12 months
12 Months
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Tidsram: 12 Months
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
12 Months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Evan Yu, Fred Hutch/University of Washington Cancer Consortium

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

8 oktober 2019

Primärt slutförande (Faktisk)

12 mars 2020

Avslutad studie (Faktisk)

12 mars 2020

Studieregistreringsdatum

Först inskickad

12 september 2018

Först inskickad som uppfyllde QC-kriterierna

22 oktober 2018

Första postat (Faktisk)

24 oktober 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 december 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

8 december 2020

Senast verifierad

1 december 2020

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • RG1001903
  • 9939 (FHCRC)
  • NCI-2018-01618 (Registeridentifierare: CTRP)
  • 5P30CA015704 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera